Biparametric versus multiparametric MRI in the diagnosis of prostate cancer

Real-time monitored MRI: A step towards personalized imaging protocol of prostate cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000030917

Enrollment

Unknown

Registered

2020-03-17

Start date

2018-01-01

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Biopsy of prostate, Pathological examination

Index test:Mp-MRI

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: This included those with elevated PSA levels (>4ng/ml) within the previous three months, or those with suspicious digital rectal examination (DRE) findings.

Exclusion criteria

Exclusion criteria: Patients were excluded if they were using 5-alpha-reductase inhibitors at time of examination or has used such during the previous six months; or if they had a previous history of prostatic biopsy, prostatic surgery, or treatment for PCa

Design outcomes

Primary

Measure	Time frame
PI-RADS;	—

Secondary

Measure	Time frame
Long diameter;volume;	—

Countries

China

Contacts

Public ContactZhang yudong

The First Affiliated Hospital of Nanjing Medical University

njmu_zyd@163.com+86 15805151704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026